NCT05382325
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients with clinically active central nervous system (CNS) metastases and/or leptomeningeal disease; Patients who have received any prior interleukin-2 (IL-2) based therapy
https://ClinicalTrials.gov/show/NCT05382325